Ultivue is setting a new standard for multiplexed immuno fluorescence solutions by characterizing immune biology to reveal spatial insights – offering a flexible option with pre-optimized, verified, application-focused immune panels. This is evident in its newest product offering: FlexVUE™.
When Ultivue’s customers expressed their feedback, they said they liked the immune-focused content and dedicated panels for whole slide imaging, but might want to exchange one or two biomarkers for others. The goal of FlexVUE is to provide customers with the ability to customize Ultivue’s current eight-marker Immuno8 FixVUE™ panel by swapping out one to two markers from the Immuno8 backbone that includes CD3, CD4, CD8, CD68, FoxP3, PD-1, PD-L1, and CK/Sox10.
Users can exchange up to any two markers with those in the Immuno8 FixVUE panel. The additional markers that can be swapped in include Ki67, GRzB, CD45RO, CD56, CD20, CD11C, CD163, CD206, CD14, CD15, CD11b, MHCII, and HLA-DR. In addition, these pre-optimized markers, plus the robust InSituPlex® technology, means that users can customize their panels without losing valuable time.
The importance of FlexVUE is clear: it is flexible, allowing users to quickly customize panels and interrogate mechanism of action, and easy to use, with pre-optimized, flexible staining that can be used across any tumor indication. FlexVUE also has rapid turnaround times – users can quickly establish assays for early-phase clinical IO studies and robust transfer to contract research organizations for deployment, demonstrating a straightforward validation process when adding new markers.
FlexVUE offers custom options that allow laboratory medicine professionals to gather a comprehensive view of the immune landscape – or delve deeper into specific cell types and areas of the tissue microenvironment. Ultivue’s out-of-the-box thinking brings pathologists and translational scientists the most innovative solutions – and, with no need to optimize and validate, all the work is done for you!
Newsletters
Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.
